Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study.

Save

Objective

Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH).

Materials and Methods

We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests.

Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention.

Results

Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05).

There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates.

Conclusion

We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.

Introduction

Benign prostatic hyperplasia (BPH) is often associated with lower urinary tract symptoms (LUTS), which can substantially affect a patient's quality of life [1]. Transurethral resection of the prostate (TURP) has often been considered the gold standard surgical technique for managing LUTS secondary to BPH for small‐to‐moderately sized prostates <80 mL [2]. Several alternative surgical options with durable outcomes have also emerged [3].

Among these, Aquablation®, which uses an image‐guided, robotically controlled, heat‐free water jet for transurethral tissue resection, has gained recognition as a promising option [4, 5, 6]. Aquablation has shown excellent, durable outcomes for moderate‐to‐severe LUTS with varying prostate volumes [5]. It is also associated with low rates of sexual dysfunction, especially compared with patients undergoing other BPH surgeries [4, 5].

Despite undergoing surgical procedures to manage BPH‐related LUTS, many patients experience a recurrence of symptoms after the initial intervention, requiring either a second surgery or resumption of LUTS‐related medication [7, 8]. This recurrence not only increases the burden of total healthcare utilization, but also negatively impacts the patient's quality of life, underscoring the importance of understanding the factors that contribute to symptom re‐emergence. Recurrence of LUTS can be attributed to the long‐term effects of bladder outlet obstruction, including bladder over‐reactivity or hypocontractility of the detrusor, remaining obstructive prostate tissue or regrowth of prostatic tissue, and procedural complications such as bladder neck stenosis [9, 10].

Recurring symptoms do not always require another surgery, as many patients simply resume LUTS‐related medications. However, the efficacy of medical treatment for BPH is limited, and these medications can cause side effects such as fatigue, decreased libido, retrograde ejaculation, dry mouth, or low blood pressure [11]. Although several studies have established the efficacy and safety of using conventional or more recent treatments such as TURP, holmium laser enucleation (HoLEP), or photo‐vaporization of the prostate (PVP) for salvage therapy, only few have addressed the use of Aquablation as a second‐line option [12, 13, 14, 15].

Given this gap in the literature, the present study aims to evaluate the safety, effectiveness, and clinical outcomes of Aquablation as a salvage therapy in patients with refractory or recurrent LUTS after initial BPH intervention.

Materials and Methods

This study was conducted through retrospective analysis of prospectively collected data in the International Collaborative Aquablation Research Urology Society (ICARUS) database, a registry of men undergoing Aquablation between 2018 and 2024 at one of four international centres. Patients with an unknown history of prior BPH intervention and patients with known or suspected neurogenic bladder were excluded from the analysis. Patients were stratified into two groups based on the presence or absence of previous BPH intervention.

The primary objective was to compare the safety, effectiveness, and clinical outcomes between the two groups. This study was approved by the institutional review board at Endeavour Health (EH20‐122).

Surgical Technique

All Aquablation therapy was performed with the patient under general anaesthesia using a robotic system with real‐time ultrasound guidance of waterjet ablation. Standardized protocols were applied across all participating centres and included targeted focal bladder neck electrocautery for haemostasis after at least two ablation passes, to minimize postoperative bleeding. Preoperative assessment and surgical technique did not differ between primary treatment and salvage therapy settings.

Outcomes

Preoperative baseline variables included age, comorbidities, medication use (alpha‐adrenergic antagonists, 5‐alpha‐reductase inhibitors, daily phosphodiesterase type 5 inhibitors, and anticoagulants or antiplatelets), serum prostate‐specific antigen (PSA), and Prostate Health Index (PHI) levels. PHI was included as a secondary exploratory marker to monitor for post‐procedural PSA‐related changes, though its role as a functional outcome measure in the BPH treatment context is not yet established. Prostate volume and presence of median lobe as well as degree of intravesical prostatic protrusion were also recorded.

Baseline clinical characteristics included maximum urinary flow rates (Qmax), post‐void residuals (PVRs), preoperative urinary retention requiring indwelling catheter or clean intermittent catheterization, International Prostate Symptom Score (IPSS), IPSS quality‐of‐life score (IPSS‐QoL), and Sexual Health Inventory for Men (SHIM) score. The Male Sexual Health Questionnaire for Ejaculatory Dysfunction was not routinely collected across sites, so ejaculatory status was captured using categorical descriptors: normal antegrade ejaculation, diminished antegrade ejaculation, or anejaculation. Patients were stratified according to the presence or absence of prior BPH intervention, and the specific intervention was recorded.

The primary outcomes were longitudinal changes in IPSS and IPSS‐QoL scores. As patient and site follow‐up in the database varied, follow‐ups were categorized as intervals occurring at 1–3, 4–8, 9–12, and 13–24 months postoperatively. All available measurements within each interval contributed to the interval‐specific comparisons.

Secondary outcomes included changes in serum PSA, PHI, Qmax, PVRs, and SHIM scores, along with rates of ejaculatory dysfunction. Perioperative characteristics such as surgery time, transfusion rates, postoperative complications as categorized on the Clavien–Dindo scale, and 30‐day hospital readmissions were also assessed. Finally, exploratory sub‐analyses were also performed in the salvage therapy group based on the type of prior BPH intervention.

Statistical Analysis

Descriptive statistics were used to summarize baseline characteristics in the study cohorts. Continuous variables were reported as medians with interquartile ranges. Group comparisons for continuous variables were made using one‐way analysis of variance for normally distributed data or the Kruskal–Wallis test for non‐normal distributions.

Categorical variables were summarized as counts and percentages, with comparisons conducted using chi‐squared or Fisher's exact tests as appropriate. Multivariable logistic regression models were fitted with candidate variables selected based on both clinical relevance pre‐specified from previous literature and statistical significance in univariable analyses (median lobe presence, baseline Qmax). Although alpha‐adrenergic use and PHI were statistically significant, they were not included in the multivariate analysis because of the high proportion of data missingness (>50%).

All statistical tests were two‐sided, and significance was defined as P < 0.05. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 4.3.2.

Results

Baseline Characteristics and Functional Metrics

Among the study population of 1887 men from the ICARUS database, 109 (5.8%) patients had undergone prior BPH intervention; the remaining 1778 (94.2%) patients served as a control cohort. Of the 109 men with a prior BPH intervention, 29 (26.6%) had undergone prostatic urethral lift (PUL), 21.1% water vapour thermal therapy (WVTT), 22 (20.2%) TURP, 22 (20.2%) PVP, and the remaining 11.9% of patients had undergone various other interventions before Aquablation (Table 1). Both the salvage and the non‐salvage groups had similar age, comorbidities, prostate volumes, and baseline serum PSA levels (all P > 0.05).

Patients who had undergone BPH intervention were associated with lower rates of median lobe presence than those in the non‐salvage group (46.3% vs 67.6%; P<0.0001) and lower Qmax (6.75 vs 8.50; P = 0.023). There were no significant differences in baseline PVR, IPSS, IPSS‐QoL, or SHIM scores (all P > 0.05). Additional baseline characteristics are detailed in Table 1.

Postoperative Functional Outcomes

When comparing the two groups in univariable (Table 2) or multivariable settings, there were no significant differences in terms of IPSS (+0.62; 95% confidence interval [CI] −1.05–2.29; P = 0.5) and IPSS‐QoL (+0.15; 95% CI −0.14–0.44; P = 0.3) score improvements throughout the follow‐up periods up to 24 months (Fig. 1) or in postoperative changes in Qmax (+1.80 mL/s, 95% CI −2.35–5.95; P = 0.4), PVR (+13.7 mL, 95% CI −48.5–75.9; P = 0.7), serum PSA levels (+0.31 ng/mL, 95% CI −0.48–1.10; P = 0.4), and PHI levels (+2.86; 95% CI −1.85–7.57; P = 0.2).

Perioperative Outcomes and Complication Rates

When comparing the two groups in univariable (Table 2) or multivariable settings, total operative time was significantly lower in the salvage group (−5.72 min, 95% CI −9.18 to −2.26; P = 0.001). No significant differences were observed between the groups in terms of takeback rates for clot evacuation or cystoscopy (odds ratio [OR] 1.22; 95% CI 0.35–4.30; P = 0.8), blood transfusion rates (OR 1.46; 95% CI 0.24–8.96; P = 0.7), 30‐day readmission rates (OR 1.11; 95% CI 0.15–8.14; P = 0.9), or perioperative complications of all grades as classified on the Clavien–Dindo scale (OR 1.05; 95% CI 0.47–2.39; P = 0.9). Throughout the follow‐up periods up to 24 months, there were no significant differences in terms of ejaculatory dysfunction rates (OR 0.71; 95% CI 0.29–1.76; P = 0.5), surgical retreatment rates (OR 0.95; 95% CI 0.08–11.7; P = 0.9), or rates of resumption of medication for BPH‐related LUTS (OR 0.78; 95% CI 0.38–1.59; P = 0.5).

Subgroup Analysis Based on Type of Prior BPH Procedure

The salvage group was divided into subgroups according to the type of prior BPH intervention for additional exploratory analyses (Table 3). The longest total operative times were observed in subgroups previously treated with prostate artery embolization. The longest Aquablation times were in the subgroup previously treated with robot‐assisted simple prostatectomy.

Prostate volumes were larger in subgroups who had previously undergone robot‐assisted simple prostatectomy and TURP, with median values at 128.8 and 103.6 mL, respectively. Patients who had undergone prostate artery embolization and WVTT had higher rates of median lobe presence than those in the other subgroups. However, it is important to note that these observations were not statistically significant between the two groups, partially due to the small sample sizes.

Discussion

We evaluated the effectiveness and safety of Aquablation as a salvage therapy for BPH using a large, international, multicentre database. We observed no statistically significant differences in safety, in improvements in voiding parameters and patient‐reported outcomes (IPSS, QoL, Qmax, PVR), or in sexual function (SHIM, ejaculatory function) when Aquablation was used as a salvage treatment for patients with refractory or recurrent LUTS, compared with primary treatment.

Baseline Characteristics and Functional Metrics

Baseline characteristics and functional metrics were largely comparable between the salvage and primary Aquablation cohorts, suggesting that differences in postoperative outcomes were unlikely driven by major demographic or clinical imbalances. Patients undergoing salvage Aquablation had similar age, comorbidity profiles, prostate volumes, and serum PSA levels. These findings indicate that patients selected for salvage therapy represent a population with persistent or recurrent disease rather than a distinctly higher‐risk cohort.

Notably, prostate volumes in both groups were similar to those typically treated with Aquablation in prior clinical trials and real‐world registries, supporting the generalizability of our cohort [4, 16]. Patients in the salvage group demonstrated lower baseline Qmax and a higher prevalence of median lobe enlargement than did patients undergoing primary Aquablation. These differences may reflect more advanced or persistent bladder outlet obstruction after prior intervention, potentially related to residual or regrowth of prostatic adenoma [17].

Despite these differences, the resulting symptom severity scores (IPSS) and QoL measures were similar between both groups.

Postoperative Functional Outcomes and Perioperative Complications

Our results also showed no significant differences between the two groups in terms of IPSS and IPSS‐QoL score improvements or in postoperative changes in Qmax, PVR, and serum PSA levels. Additionally, no significant differences were observed in terms of takeback rates for clot evacuation or cystoscopy, blood transfusion rates, 30‐day readmission rates, or perioperative complications of all grades as classified on the Clavien–Dindo scale. These findings further extend the already established effectiveness and safety of Aquablation to the salvage therapy setting.

A smaller study presenting a series of 26 patients undergoing salvage Aquablation compared with 174 patients undergoing primary Aquablation presented similar results [18]. The authors found no significant differences in functional outcomes or perioperative complications. The current study further strengthens these results in a larger, international, multicentre setting.

Salvage Therapy Context

Management of recurrent or refractory LUTS after prior BPH surgery remains clinically challenging [19]. Symptom recurrence may result from incomplete initial tissue removal, prostatic regrowth, bladder dysfunction, or postoperative complications such as bladder neck contracture or urethral stricture [20]. Repeat procedures are generally associated with increased technical difficulty and higher complication risks due to altered anatomy and fibrosis [21].

Interestingly, our results demonstrate similar Aquablation times between the salvage and primary treatment groups, and total operative time was shorter in the salvage group. This suggests that prior intervention did not significantly affect the procedural efficiency of Aquablation. Several studies reported similar surgical outcomes for salvage patients with other treatment options.

A study by Oh et al. that evaluated the feasibility of HoLEP for salvage cases reported that patients with refractory BPH after a first intervention had more residual tissue around the verumontanum, suggesting an incomplete resection of excess prostate tissue [22]. However, similar to the current study, total operative time was not significantly different between the salvage group and the primary group [22].

Sexual Function Preservation

An important finding of the present study is the preservation of sexual function in the salvage cohort. Sexual function outcomes, including changes in SHIM scores and ejaculatory dysfunction rates, did not differ significantly between the two groups. Preservation of sexual function is a major advantage of Aquablation compared with some conventional surgical therapies.

Randomized trials have demonstrated substantially lower rates of postoperative ejaculatory dysfunction with Aquablation than with TURP [4] or HoLEP [23]. The findings from the present study extend this advantage of Aquablation in the salvage therapy setting, in which patients may have already experienced treatment‐related morbidity from prior interventions. As baseline ejaculatory status was not available for the salvage cohort, these postoperative outcomes should be interpreted with caution.

Durability of Aquablation

Durability is a key metric in any intervention or surgery for BPH‐related LUTS. Several studies have evaluated the long‐term durability and retreatment rates of different surgical techniques. For instance, Helman et al. reported 5‐year reoperation rates at 24.5% after transurethral microwave therapy and 22.3% after PUL [7].

The lowest surgical retreatment rate was observed in patients undergoing HoLEP (7.0%), which has historically demonstrated excellent and durable outcomes [7, 24], However, the WATER III trial reported that patients undergoing Aquablation experienced superior ejaculation preservation and lower rates of short‐term stress urinary incontinence than those undergoing HoLEP [23]. Real‐world studies have also demonstrated non‐negligible rates of transient stress urinary incontinence in patients undergoing HoLEP [25]. Thus, salvage therapy with Aquablation holds appeal as a relatively durable retreatment option after prior surgery, especially in men wishing to preserve ejaculatory function and continence.

Similarly, TURP demonstrated a 5‐year retreatment rate of approximately 7.0% [8], whereas the pivotal UroLift trial by Roehrborn et al. reported a surgical retreatment rate of 13.6% [26], and McVary et al. reported retreatment rates of 4.4% for patients in a trial of water vapor therapy (Rezūm™) [27].

Subgroup Analysis

The present study also provides insight into outcomes across a heterogenous range of prior BPH interventions, including minimally invasive therapies and resective procedures. Patients undergoing salvage Aquablation after procedures such as PUL or WVTT demonstrated safety and perioperative outcomes similar to those who received it after TURP or PVP. Notably, no patients in the salvage group had previously undergone HoLEP.

This may potentially reflect referral patterns and regional practice variations as well as long‐term efficacy associated with HoLEP, as reported in the literature [28, 29]. However, no associations can be drawn regarding this point based on our results. Although subgroup analyses were limited by the small sample sizes, these findings suggest that Aquablation may represent a versatile retreatment option across a wide spectrum of prior interventions.

This flexibility is clinically relevant as minimally invasive therapies are increasingly used as first‐line treatments and may be associated with higher retreatment rates over time [30].

Limitations

Several limitations to this study should be acknowledged. First, the retrospective analysis of prospectively collected data may introduce selection bias and confounding. Propensity score matching and inverse probability weighing were not applied as the limited size and incomplete covariate capture of the salvage cohort may have yielded unstable estimates, and residual confounding cannot be excluded.

Second, the salvage cohort represented a relatively smaller proportion of the overall study population, which limited the statistical power of subgroup analyses according to prior BPH intervention and restricted the ability to detect small but clinically meaningful differences between treatment groups, as seen with substantially wider CIs for low‐frequency outcomes such as transfusion and surgical retreatment rates. Third, follow‐up duration and completeness varied across centres, so outcomes were analysed within pre‐defined follow‐up intervals rather than at uniform time points. Within‐patient correlation was not formally modelled through a mixed‐effects approach, and these interval‐based comparisons do not exploit the full longitudinal correlation structure.

Fourth, ejaculatory function was captured using categorical descriptors rather than the validated Male Sexual Health Questionnaire for Ejaculatory Dysfunction, which was not routinely collected across sites. In addition, baseline ejaculatory status was not systematically captured. This limits the strength of conclusions regarding ejaculatory function preservation.

Fifth, prostate volume at the time of the initial BPH intervention was not available in the ICARUS database, which limits the ability to assess and account for the extent of tissue removal, residual adenoma, and its potential contribution to symptom recurrence. Sixth, the ICARUS database did not capture the exact nature of Clavien–Dindo complications outside of categorical classification, limiting our insight into complication profiles. Seventh, the ICARUS database did not systematically capture urodynamic studies or detailed aetiologies of symptom recurrence, limiting our ability to completely distinguish contributors to prior treatment failure.

Based on our evaluation of the 1887 patients who underwent Aquablation therapy in the ICARUS database, no statistically significant differences in safety or effectiveness were observed for Aquablation as a salvage therapy to treat recurrent LUTS after a failed prior BPH intervention while preserving sexual function in the majority of men.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors.

Disclosure of Interests

Alexander Glaser has a relationship with PROCEPT BioRobotics Corporation that includes consulting or advisory, speaking and lecture fees, and travel reimbursement and a relationship with Emano Metrics that includes board membership and equity or stocks. Inderjit Singh and Shawn Marhamati have a relationship with PROCEPT BioRobotics Corporation that includes consulting or advisory. James Kearns, Kevin Zorn, and Brian Helfand have a relationship with PROCEPT BioRobotics Corporation that includes consulting or advisory, speaking and lecture fees, and travel reimbursement.

All other authors declare no conflicts of interest.

Related articles

PubMed

Knowledge and awareness of benign prostatic hyperplasia among the general population in Makkah, Saudi Arabia: A cross-sectional study.

ABSTRACT Background: Benign prostatic hyperplasia (BPH) is a common age-related condition that can significantly affect quality of life and lead to serious urinary complications. Public awareness is essential for early recognition and timely management. Aim: This study aimed to evaluate the level of knowledge and awareness of BPH among adult men in Makkah, Saudi Arabia. Methods: A cross-sectional study was conducted between December 2025 and January 2026 using a previously validated questi...

PubMed

A transition zone enriched WIF1(+) basal cell subtype is associated with benign prostatic hyperplasia.

Abstract The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the transition zone (TZ). Through extensive single‐cell RNA sequencing (scRNA‐seq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1, VCAN, and NRG1, among other genes, that was s...